Drug Release Analysis Framework

Stanford Appel Lab - Study Pharmacokinetics Project: Pharmacokinetic Data Modeling and Visualization Tool. Primary usage for drug delivery studies. Web app written in HTML/CSS/JS using libraries from CDNs so it can be deployed on static pages.

Stanford Appel Lab - Study Pharmacokinetics Project: Pharmacokinetic data modeling and visualization tool. Primary usage for drug delivery studies. Python supporting files and an example Jupyter Notebook for configuring custom PK analysis

Open-source computational pipeline for CNS drug-delivery formulation screening — real PBPK, DLVO colloidal stability, AutoDock Vina docking, and ChEMBL-trained QSAR, with a public audit trail of its own bugs. Research prototype, not clinically validated.

With a focus on BBB modulation, safety, and translational relevance, this academic research project investigates targeted ultrasound and microbubble-mediated approaches for improved CNS and brain tumor drug delivery.

This model makes predictions on LNP Encapsulation Efficiency % based on training data acquired from the LNP Atlas project

Construct-validity audit of the standard blood–brain barrier (BBB) peptide benchmark: an identity-controlled re-evaluation + shared-source provenance/overlap map, with an open, CPU-reproducible evaluation harness. Do these predictors measure penetration, or their benchmarks?

CPP classification (F1 0.80) and cellular uptake regression (R² 0.79) on the POSEIDON database · DataCon 3.0 · Python · RDKit · CatBoost

Personal academic site for Molham Sakkal - Cancer Cell Biology and Drug Delivery research at Al Ain University HBRC. Auto-synced from Google Scholar weekly.

MATLAB code for Ouyang et al. (2020) - A dose threshold to enhance nanoparticle tumour delivery. Quantification of nanoparticle concentration as a function of distance from blood vessels from 3D light-sheet microscopy images.

Official repository of "A Machine Learning Framework for Predicting Entrapment Efficiency in Niosomal Particles".

In silico approaches for designing and predicting highly effective cell penetrating peptides

Computational simulation of PLGA nanoparticle transport, drug release, and tumor response using finite difference methods in Python.

BreezeBio, Inc. (formerly GenEdit) is a clinical-stage genetic medicines company based in South San Francisco, California, solving the central delivery problem of gene editing and genetic medicine.

Granza Bio is an early-stage biotechnology company reprogramming immunity for target-specific medicines. Founded in 2024 by Dr. Ashwin Nandakumar, Dr. Ashwin Jainarayanan, and Prof. Michael Dustin, the company builds on the discovery of "attack particles" — killing entities released by cytotoxic immune cells, characterized in Prof.

Intersect ENT was a medical device company based in Menlo Park, California that developed drug-eluting, bioresorbable sinus implants for patients with chronic rhinosinusitis. Its PROPEL family of steroid-eluting implants maintains sinus patency and delivers localized mometasone furoate to the sinus mucosa following endoscopic sinus surgery, while…

Envisia (Envisia Therapeutics, Inc.) was a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, spun out of Liquidia Technologies to apply PRINT (Particle Replication In Non-wetting Templates) particle-engineering to sustained-release ophthalmic therapeutics.

Method components (convection-diffusion residual, release-schedule optimizer) for PINN-based pulsatile flow and targeted drug delivery (J. Pharmacy and Bioallied Sciences, Dec 2025). Not a runnable pipeline — see Status.

BreezeBio (formerly GenEdit) is a South San Francisco genetic-medicine company developing precision-delivered nucleic acid therapies for autoimmune disease and oncology. Its proprietary NanoGalaxy platform uses non-lipid, hydrophilic polymer nanoparticles of tunable size, charge, and composition to selectively deliver DNA, RNA, and…

Liquidia Corporation (NASDAQ: LQDA) is a biopharmaceutical company focused on the development and commercialization of inhaled therapies for cardiopulmonary disease, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).